Aeolian Biotech: a big pharma Pneumococcal Conjugate Vaccine opportunity in a small biotech.
Aeolian Biotech is developing an improved pneumococcal conjugate vaccine (iPCV) that is designed to cover the serotypes causing invasive disease. Our vaccine composition covers 95% of invasive serotypes in the US adults compared to approximately 60% for other vaccines. Our team includes three key leaders from the Prevnar development team which enables our efficient development strategy. We are currently raising capital that is being used to initiate development. We plan to raise our series A round in late 2023 that will support the company through clinical proof of concept results.
Company Details
- Employees
- 3
- Founded
- 2022
- Address
- Lincoln, Ne 68506, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aeolianbiotech.com
- HQ
- Lincoln, NE
Aeolian Biotech Corp. Questions
Aeolian Biotech Corp.'s website is http://www.aeolianbiotech.com
Aeolian Biotech Corp.'s LinkedIn profile is https://www.linkedin.com/company/aeolian-biotech-corp
Aeolian Biotech Corp. has
3 employees.
View email and phone details for 3
employees at Aeolian Biotech Corp..
Aeolian Biotech Corp.'s industry is
Biotechnology Research
Aeolian Biotech Corp.'s top competitors are
Adjuvance Technologies, Inc,
Rpm Pharma Consulting, Inc.,
Freud Cigar Co.,
Lir Life Sciences,
Bunyavax,
Q-Vant Biosciences,
Synbiotic Health,
Klotho Therapeutics, Inc.,
Epicrop Technologies Inc,
Licorbio.
Aeolian Biotech Corp.'s categories are Biotechnology Research
Aeolian Biotech Corp.'s founding year is 2022
